GTBP
Income statement / Annual
Last year (2024), GT Biopharma, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, GT Biopharma, Inc.'s net income was -$13.16 M.
See GT Biopharma, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$27,000.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$4,000.00
|
$7,000.00
|
$2,000.00
|
$1,000.00
|
$2,000.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$4,000.00
|
-$7,000.00
|
-$2,000.00
|
-$1,000.00
|
$25,000.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0.93
|
| Research and Development Expenses |
$5.80 M
|
$6.47 M
|
$8.81 M
|
$9.59 M
|
$485,000.00
|
$1.67 M
|
$9.07 M
|
$1.07 M
|
$975,000.00
|
$1.00 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$47.92 M
|
$6.28 M
|
$9.79 M
|
$12.49 M
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$8.57 M
|
$7.11 M
|
$12.45 M
|
$47.92 M
|
$6.28 M
|
$9.79 M
|
$12.49 M
|
$134.50 M
|
$8.40 M
|
$7.95 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
-$242,760.00
|
-$12.60 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$14.36 M
|
$13.58 M
|
$21.26 M
|
$57.52 M
|
$6.76 M
|
$11.46 M
|
$21.55 M
|
$135.57 M
|
$9.37 M
|
$8.95 M
|
| Cost And Expenses |
$0.00
|
$13.58 M
|
$21.26 M
|
$57.52 M
|
$6.76 M
|
$11.46 M
|
$21.55 M
|
$135.57 M
|
$9.37 M
|
$8.95 M
|
| Interest Income |
$402,000.00
|
$567,000.00
|
$292,000.00
|
$38,000.00
|
$3,320.00
|
$2,128.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$8,000.00
|
$718,000.00
|
$3.32 M
|
$2.13 M
|
$9.12 M
|
$8.60 M
|
$6.56 M
|
$17.04 M
|
| Depreciation & Amortization |
$0.00
|
$13.58 M
|
$21.26 M
|
$57.52 M
|
$4,000.00
|
$4,000.00
|
$7,000.00
|
$2,000.00
|
$1,000.00
|
$2,000.00
|
| EBITDA |
-$14.36 M |
$5.98 M |
-$20.97 M |
-$57.48 M |
-$24.98 M |
-$11.45 M |
-$250.06 M |
-$135.57 M |
-$9.37 M |
-$8.93 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-330.56
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-330.63
|
| Total Other Income/Expenses Net |
$1.20 M
|
$5.98 M
|
$373,000.00
|
-$498,000.00
|
-$21.53 M
|
-$22.59 M
|
-$9.12 M
|
-$7.68 M
|
$19.14 M
|
-$12.53 M
|
| Income Before Tax |
-$13.16 M
|
-$7.60 M
|
-$20.88 M
|
-$58.01 M
|
-$28.30 M
|
-$38.65 M
|
-$259.19 M
|
-$143.25 M
|
$21.03 M
|
-$32.73 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-1212.07
|
| Income Tax Expense |
$0.00
|
$0.00
|
-$381,000.00
|
$680,000.00
|
$3.32 M
|
$2.13 M
|
-$228.52 M
|
$7.68 M
|
-$30.41 M
|
$17.04 M
|
| Net Income |
-$13.16 M
|
-$7.60 M
|
-$20.50 M
|
-$58.69 M
|
-$31.62 M
|
-$40.78 M
|
-$259.19 M
|
-$143.25 M
|
$21.03 M
|
-$32.73 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-1212.07
|
| EPS |
-6.94 |
-5.64 |
-19.3 |
-6.78 |
-3.05 |
-10.91 |
-87.7 |
-145.22 |
4390.11 |
-69629.79 |
| EPS Diluted |
-6.94 |
-5.64 |
-19.3 |
-6.78 |
-3.05 |
-10.76 |
-87.7 |
-145.22 |
4390.11 |
-69629.79 |
| Weighted Average Shares Out |
$1.90 M
|
$1.35 M
|
$1.06 M
|
$8.65 M
|
$10.38 M
|
$3.74 M
|
$2.96 M
|
$986,419.00
|
$4,791.00
|
$470.00
|
| Weighted Average Shares Out Diluted |
$1.90 M
|
$1.35 M
|
$1.06 M
|
$8.65 M
|
$10.38 M
|
$3.79 M
|
$2.96 M
|
$986,419.00
|
$4,791.00
|
$470.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
